The subject of the order is the delivery of Rapamune 1 mg (Sirolimusum) used in the framework of the non-commercial clinical trial of DIPGen together with labelling on the basis set out in the proposed contract provisions in quantities resulting from current needs and within the deadlines arising from the concluded contract.

Rapamune 1 mg (Sirolimusum) tabl. irritated, pack 30 pieces. Marketing authorisation No EU/1/01/171/007 including labelling.